Cerium single-atom catalysts-armed Lactobacillus reuteri for multipronged anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease.
10.1016/j.apsb.2025.06.022
- Author:
Yinying PU
1
;
Shaorong HUANG
2
;
Shuang GAO
3
;
Yangying DUAN
1
;
Wenhao LI
1
;
Qiyue LI
1
;
Han LIN
4
;
Kun ZHANG
1
;
Min ZHOU
3
;
Wencheng WU
1
Author Information
1. Central Laboratory and Department of Medical Ultrasound, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
2. Institute of Geriatrics, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang 330006, China.
3. Digestive Endoscopy Center, Shanghai Fourth People's Hospital to Tongji University, Shanghai 200081, China.
4. Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China.
- Publication Type:Journal Article
- Keywords:
Antioxidant therapy;
Catalytic;
Cerium single-atom catalyst;
Gut microbiota;
Inflammatory bowel disease;
Intestinal fibrosis;
Probiotic;
Reactive oxygen radicals
- From:
Acta Pharmaceutica Sinica B
2025;15(10):5400-5415
- CountryChina
- Language:English
-
Abstract:
Simultaneous management of intestinal mucosal barrier dysfunction and gut microbiota dysregulation represents a significant challenge in the treatment of inflammatory bowel disease (IBD). Herein, we report a novel system that integrates multi-enzyme mimicking cerium single-atom nanocatalysts (CeSACs) with Lactobacillus reuteri probiotics (LR@CeSACs) for multipronged management of IBD. In this system, CeSACs demonstrate robust multi-enzyme activities across a broad pH range, effectively scavenging elevated reactive oxygen species, downregulating pro-inflammatory cytokines, and suppressing the expression of fibrosis-related genes. Moreover, probiotics promote the targeting and retention of the CeSACs for sustained catalytic antioxidant therapy. In turn, the inflammation relief enabled by CeSACs promotes bacterial viability, allowing for the rapid reshaping of intestinal barrier function and the restoration of gut microbiota. Therefore, LR@CeSACs exhibit excellent catalytic anti-inflammatory and anti-fibrotic therapeutic effects, as well as a certain prophylactic effect, as demonstrated in several murine models.
